5 Stocks Pushing The Health Care Sector Lower

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

The Dow Jones Industrial Average (^DJI) steady at 13,953 as of Wednesday, Jan. 30, 2013, 11:50 AM ET. The NYSE advances/declines ratio sits at 1,129 issues advancing vs. 1,699 declining with 163 unchanged.

The Health Care sector currently sits down 0.3% versus the S&P 500, which is down 0.0%. On the negative front, top decliners within the sector include Herbalife (HLF), down 6.8%, Haemonetics Corporation (HAE), down 6.4%, Vertex Pharmaceuticals (VRTX), down 3.8%, St Jude Medical (STJ), down 1.4% and Aetna (AET), down 1.3%. Top gainers within the sector include Isis Pharmaceuticals (ISIS), up 12.2%, HCA Holdings (HCA), up 2.2%, Sanofi (SNY), up 1.0%, Novo Nordisk A/S (NVO), up 0.7% and Biogen Idec (BIIB), up 0.6%.

TheStreet Ratings group would like to highlight 5 stocks pushing the sector lower today:

5. Parexel International Corporation (PRXL) is one of the companies pushing the Health Care sector lower today. As of noon trading, Parexel International Corporation is down $1.30 (-3.8%) to $32.56 on heavy volume Thus far, 1.6 million shares of Parexel International Corporation exchanged hands as compared to its average daily volume of 678,000 shares. The stock has ranged in price between $31.23-$32.74 after having opened the day at $32.50 as compared to the previous trading day's close of $33.86.

PAREXEL International Corporation, a biopharmaceutical services company, provides clinical research, medical communications, consulting, commercialization, and advanced technology products and services to the pharmaceutical, biotechnology, and medical device industries worldwide. Parexel International Corporation has a market cap of $2.0 billion and is part of the drugs industry. The company has a P/E ratio of 29.8, above the S&P 500 P/E ratio of 17.7. Shares are up 14.8% year to date as of the close of trading on Tuesday. Currently there are 5 analysts that rate Parexel International Corporation a buy, 1 analyst rates it a sell, and 3 rate it a hold.

TheStreet Ratings rates Parexel International Corporation as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and solid stock price performance. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full Parexel International Corporation Ratings Report now.

EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass

4. As of noon trading, Onyx Pharmaceuticals (ONXX) is down $1.79 (-2.3%) to $76.45 on light volume Thus far, 234,850 shares of Onyx Pharmaceuticals exchanged hands as compared to its average daily volume of 1.0 million shares. The stock has ranged in price between $76.35-$78.20 after having opened the day at $78.09 as compared to the previous trading day's close of $78.24.

Onyx Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies that target the molecular mechanisms that cause cancer in the United States and internationally. Onyx Pharmaceuticals has a market cap of $5.2 billion and is part of the drugs industry. The company has a P/E ratio of 66.8, above the S&P 500 P/E ratio of 17.7. Shares are up 2.6% year to date as of the close of trading on Tuesday. Currently there are 14 analysts that rate Onyx Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Onyx Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and compelling growth in net income. However, as a counter to these strengths, we find that we feel that the company's cash flow from its operations has been weak overall. Get the full Onyx Pharmaceuticals Ratings Report now.

EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass

3. As of noon trading, Zimmer Holdings (ZMH) is down $0.67 (-0.9%) to $74.75 on light volume Thus far, 394,125 shares of Zimmer Holdings exchanged hands as compared to its average daily volume of 1.1 million shares. The stock has ranged in price between $74.26-$75.05 after having opened the day at $74.97 as compared to the previous trading day's close of $75.42.

Zimmer Holdings, Inc., through its subsidiaries, engages in the design, development, manufacture, and marketing of orthopedic reconstructive devices, spinal and trauma devices, dental implants, and related surgical products in the Americas, Europe, and the Asia Pacific. Zimmer Holdings has a market cap of $13.0 billion and is part of the health services industry. The company has a P/E ratio of 17.5, below the S&P 500 P/E ratio of 17.7. Shares are up 12.6% year to date as of the close of trading on Tuesday. Currently there are 11 analysts that rate Zimmer Holdings a buy, no analysts rate it a sell, and 16 rate it a hold.

TheStreet Ratings rates Zimmer Holdings as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, largely solid financial position with reasonable debt levels by most measures, attractive valuation levels, growth in earnings per share and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Zimmer Holdings Ratings Report now.

EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass

2. As of noon trading, Regeneron Pharmaceuticals (REGN) is down $1.83 (-1.0%) to $173.13 on light volume Thus far, 117,315 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 839,700 shares. The stock has ranged in price between $172.79-$174.99 after having opened the day at $174.49 as compared to the previous trading day's close of $174.96.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of serious medical conditions in the United States. Regeneron Pharmaceuticals has a market cap of $16.1 billion and is part of the drugs industry. The company has a P/E ratio of 86.8, above the S&P 500 P/E ratio of 17.7. Shares are down 0.1% year to date as of the close of trading on Tuesday. Currently there are 7 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Regeneron Pharmaceuticals Ratings Report now.

EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass

1. As of noon trading, Celgene Corporation (CELG) is down $1.04 (-1.0%) to $98.16 on average volume Thus far, 1.6 million shares of Celgene Corporation exchanged hands as compared to its average daily volume of 3.6 million shares. The stock has ranged in price between $97.85-$99.73 after having opened the day at $99.00 as compared to the previous trading day's close of $99.20.

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes various therapies to treat cancer and immune-inflammatory related diseases primarily in the United States and Europe. Celgene Corporation has a market cap of $41.9 billion and is part of the drugs industry. The company has a P/E ratio of 20.2, above the S&P 500 P/E ratio of 17.7. Shares are up 26.1% year to date as of the close of trading on Tuesday. Currently there are 23 analysts that rate Celgene Corporation a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Celgene Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Celgene Corporation Ratings Report now.

EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR (XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care (RXD).

A reminder about TheStreet Ratings group: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

For more information on Celgene Corporation click any of the following:

• Celgene Corporation Stock Price

• Celgene Corporation Analyst Ratings

• Celgene Corporation Key Stats & Profile

• Celgene Corporation Earnings

• Celgene Corporation Ratio Comparison

• Celgene Corporation Growth Rates

• Celgene Corporation Balance Sheet

• Celgene Corporation Cash Flow

• Celgene Corporation Income Statement